Overview

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and safety of paliperidone palmitate in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.
Treatments:
Paliperidone Palmitate